The World Health Organisation estimates that 150 million people worldwide suffer from asthma and that chronic obstructive pulmonary disease is the fourth greatest cause of death worldwide.
AstraZeneca’s respiratory portfolio includes Symbicort, a combination of the inhaled steroid budesonide and the long-acting bronchodilator formoterol delivered via the gold-standard dry-powder inhaler Turbuhaler. Symbicort is the only inhaled steroid/bronchodilator combination inhaler that enables asthma patients to adjust their treatment dose to control the natural variations in their disease using the same inhaler.
Product range
More information about our products is available by clicking on the names below.
| Brand Name | Generic Name |
|---|---|
| Accolate, Accoleit, Vanticon | zafirlukast |
| Bambec, Oxeol | bambuterol |
| Bricanyl | terbutaline |
| Oxis | formoterol |
| Pulmicort, Spirocort | budesonide |
| Rhinocort | budesonide |
| Symbicort | budesonide/formoterol |
| Delivery devices for AstraZeneca products |
|---|
| NebuChamber |
| Turbuhaler |
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Not signed in
Page tools
Share price
- London
-
27.02 GBP - New York
-
44.93 USD - Stockholm
-
314.10 SEK
At 05-Nov-2009 21:45 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
